Cellosaurus SK-HEP-1 (CVCL_0525)

Cell line name SK-HEP-1
Synonyms SK-Hep-1; SK-Hep1; Sk-Hep1; SK Hep1; SKHEP-1; SKHEP1; SKHep1; SK_HEP1
Accession CVCL_0525
Resource Identification Initiative To cite this cell line use: SK-HEP-1 (RRID:CVCL_0525)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
From: Memorial Sloan-Kettering Cancer Center; New York; USA.
Registration: Memorial Sloan-Kettering Cancer Center Office of Technology Development; SK1980-535.
Characteristics: Has lost chromosome Y.
Doubling time: ~30 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Secretome proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Hepatocellular carcinoma (NCIt: C3099)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_A040 (F2.4E5); CVCL_A041 (F2.5B6); CVCL_A042 (P1.1A3); CVCL_A046 (P1.4D6); CVCL_AU01 (SK-Hep-1-FIX); CVCL_6019 (SK-Hep-1-NIS); CVCL_M182 (SK-Hep-1/CDDP)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; KCLB; PubMed=11416159; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,12 (ATCC; Cosmic-CLP; DSMZ; ECACC; KCLB; PubMed=25877200)
11 (CLS)
D13S3178,12
D16S53912
D18S5113,15
D19S43312,15.2
D21S1129,31
D2S133820,23
D3S135816
D5S81810,13
D7S8208,11
D8S117913,14
FGA17
Penta D13,14
Penta E13,21 (CLS)
13 (PubMed=25877200)
TH017,9
TPOX9
vWA14,17
Web pages http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/s/cell-lines-detail-397.html
https://www.mskcc.org/research-advantage/support/technology/tangible-material/sk-hep-1-human-hepatic-adenocarcinoma-cell-line
http://tcpaportal.org/mclp/
Publications

DOI=10.1007/978-1-4757-1647-4_5
Fogh J., Trempe G.L.
New human tumor cell lines.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x
Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.J., Revillard J.-P.
Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.
Eur. J. Biochem. 165:699-704(1987)

PubMed=8389256; DOI=10.1093/carcin/14.5.987
Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis 14:987-992(1993)

PubMed=12029633; DOI=10.1053/jhep.2002.33683
Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology 35:1476-1484(2002)

PubMed=20069059; DOI=10.1155/2010/437143
Srisomsap C., Sawangareetrakul P., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S., Svasti J.
Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.
J. Biomed. Biotechnol. 2010:437143-437143(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23505090; DOI=10.1002/hep.26402
Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Hepatology 58:706-717(2013)

PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218-2218(2013)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311
Cevik D., Yildiz G., Ozturk M.
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
World J. Gastroenterol. 21:311-317(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; HTB-52
CLS; 300334/p485_SK-HEP-1
DSMZ; ACC-141
ECACC; 91091816
ICLC; HTL10001
KCB; KCB 2013038YJ
KCLB; 30052
Cell line databases/resources CLDB; cl4312
CLDB; cl4313
CLDB; cl4314
CLDB; cl4315
CLDB; cl7214
CCLE; SKHEP1_LIVER
CCRID; 3111C0002000000060
CCRID; 3131C0001000700109
CCRID; 3142C0001000000133
CGH-DB; 9071-4
Cosmic-CLP; 909719
GDSC; 909719
LINCS_LDP; LCL-1941
TOKU-E; 3132
Ontologies BTO; BTO:0003477
CLO; CLO_0009037
MCCL; MCC:0000425
Biological sample resources BioSample; SAMN01821598
BioSample; SAMN01821664
BioSample; SAMN03472884
Chemistry resources ChEMBL-Cells; CHEMBL3307741
ChEMBL-Targets; CHEMBL614912
Gene expression databases GEO; GSM481451
GEO; GSM565878
GEO; GSM887578
GEO; GSM888661
GEO; GSM936776
GEO; GSM1374879
GEO; GSM1670432
Polymorphism and mutation databases Cosmic; 684195
Cosmic; 928139
Cosmic; 932990
Cosmic; 979728
Cosmic; 873394
Cosmic; 735607
Cosmic; 909719
Cosmic; 1187333
Cosmic; 1518231
Cosmic; 2162539
Cosmic; 2321042
Proteomic databases PRIDE; PXD002957